A Medscape opinion roundup asks whether microdosing tirzepatide carries too much risk and whether surgery still matters, plus why sweet-and-salty snacks hook us.
Recap by typeshit. Full story at Medscape.
European regulators first raised NAION, a rare optic nerve condition sometimes called an eye stroke, as a possible risk more than 15 months ago.
Obesity doctor Spencer Nadolsky takes on six popular misconceptions about Ozempic in a quick social video. The caption doesn't say which myths are covered.
Users described more appetite, fatigue, extra energy and insomnia. An analysis of Reddit comments, not a clinical trial, so the findings come from self-reports.
Online sellers pitch peptides for weight loss, anti-aging and muscle gain, and Gavin Coote's full story looks at the risks of products nobody regulates.
Therapist Zoë Bisbing and novelist Rainbow Rowell describe moms on Ozempic-style drugs pushing daughters to start, and the body-image fights that follow.
The poster says the reported nausea and vomiting rates look far lower than for retatrutide, semaglutide or tirzepatide, and calls that suspicious. An opinion, not a finding.
Loading…